T HE PATI IOOENESIS OF INTESTINAL inflammalion in general, anJ in, flammacory bowel disease (IBO) m particular, can be divided into cwo stages. The first stage is the initiating event which trigger:, the mflamrnaton· response, hut m lBD the m1t1acmg event is unknown. The second stage 1s the amplification of the inflammatory response which mvolves a numhcr ol inflammatory cel ls indudmg lymphocytes, mast cells, macrophages and neutrophib. The amplificatton of the inflammatory response is contrnllcJ by solu ble mediators inc.ludmg histamine, serotonin, proJucts of the complement pathway, prostaglandirn, and leukotri· enes. This second stage, the ampltfica· tion of the inflammatory response, ti important 111 the pathogenesis of IBD fo r two reasom. First, it is lhe amplifica· tion of the inflammatory respome, and not the initiating event, which 1s the cause of the tissue destruction and the hisrolog1c and functional changes char, actenmc of IBO. Second, those Jnigi which are effective in the treatment of IBO appear to exert their rhcrapcuuc effects by moJulatmg the rmduction of soluble mediators ( l,2) . Moreover, as long as the 111itiating e\'cnt remains unknown, it 1s likely that further advances tn the mcJ1cal thcrary of IBO will result from rharmacnlog1( modulat1on of inflammatory mediators.
PROSTAGLANDINS IN IBO
Few investigations have fuu1sed directly on mediators of the inflammatory process 111 IRD. Prostaglandins, which arc found in mLrease~I concentrations in inflammatory exudates, have received the most attcnrion (3, 4) . High levels of prostagland1m arc present m rectal muc11sa and 111 scrum tn !BD and high levels of prnstagl.111din metabolites arc found 111 the urine. Prostaglandin levels decline when patients with (Bl) arc treated with either corticosteroids or sulrhasalazine. However, prostaglandins a lso declme when IBD pauenrs arL· treated with nonstcroidal anu-inflammatory drugs (eg, mdomethacm), but pancnts do not ihow cl1111cal improvement. There is, 111 fact, some evidence that non-,tcro1dal ,1genrs may mLrease the ,;everity of I BD. These last f1 ndings sugcst that prosraglandms m,1y not he important mcJ1acors 111 IBD and that the mechanism of act1un of corticosteroids and sulphasala:mc may nnt relate to the inhibition of rrostaglandin synthesis.
LIPOXYGENASE PRODUCTS IN IBD
More recently some work has been Jin:cted at the potenual wk· of hp.>xygenase products 111 the pathogenesis of !RD (3, 5 (6, 7) . In compamon, arach,donatc 1111.ubated with normal colonic mucosa is estcrified into phospholip1ds and rnglyccndes, hut 1s not metabolized by lipoxygcnase or cvclooxygcnase. The metabolism of arac.h1dnnatc by IBD mucosa 1s remarkable m that the exogenous araLh1dunme b merahnlt:ed by lipoxygcnasc and cydooxygcnase even in the abcnce of added stimuli. This is 111 contrast to neutmphils, for examrle, 111 which exogenous arachidonate is metabolized only in the presence of a stimulus.
In order to detenn111c whether or not these lipoxygenase products exist in the tissue endogenously, lipids were extracted from the colonic mucosa and separated hy high perfonnancc l1qu1d chromatography (I !PLC). LTB4, 12-HETE, 15-HETE and 5-l LETE were present endogenously 111 the !BO mucosa. Whereas normal mucosa contams less than 5 ng L TB4/g mucosa ( wh ,ch was the lower limit of scn-sit1v1ty of the assay), the average L TB.t content ot lBD mucnsa was 254 ng/g mucosa (7) . If this concentration of L TB4 wa~ 111 st)lution, 1t wmild be well with111 the b1ologically active range. In addmon, mcuhatmn of arnchidnnatc with rccrnl mucosa! biopsies from lBD patients results in che synthesis of the sulphidoleukotnenes (L TC.1, L Tl).1, L TE,i) 111 addition to LTB4 (8) .
There is also 111 \'iVt) evidence for the cnhanLcd producttnn nf L TR4 111 ulcerative colitis (9) . Bags 1>t dialysis tubtng were placed m the rectums of paucnts wnh ulcerative colitis and left in place for 4 h. Clostridium LLfficile-assnc iated col I tis ( 11 ). All patients had endoscopically proven rcct,11 mfl,lmm,mlln. Con cenrratinm 11f PGE2, PGFZ<t and thrnmboxane 82, hue nor 6-ketn PGF1a, were 1111,;reased 111 all disease groups Cllmpared w11h controls. Con-cenrrati1ms nf L TB4 were suhstantially 111Lrcased m ulcerative colitis, hut in Crohn\ discasl' and C d,fficile-associated col ms only those patients with rectal ulcers showed elevat1nns llf L TB4. Thus, the role of L TB4 111 the parhugcnes1s of ulcerauvc col 1t1s may he greater th,m its role 111 Cmhn's db-
ARACHIDONATE METABO-LISM IN ANIMAL MODELS OF INTESTINAL INFLAMMATION
ThL·rc arc nn rntally samfactory ammal models of human I BO; however ..,tudies nf e1cnsano1d pruduuion in three animal m11Jels of 111tcstinal 111-flammat1on revealed ,triking s1rntlant1e, rn chat seen 111 18D. Zipscr measured PGE2 L TB4 and L TC4 levcb by rcual dialysis 111 rabbits 111 whom colitis had been 111duced wnh immune ..:omrlcxL'S ( 12) . Colitb was associated with enhanLed synthesis of all three compounds, L TB4 > P(;E 2 >> LTC4.
There was good correlation between elevated levds of L TB4 and presence of histolog1c inflammation and diarrhea rroduct1on. AraLhadonate metabolism was alw assayed in a second model of 111test111al 111flammat1on -acetiL acid tulms m the rat.
Dilute acctiL aL1J was injected into rat colon and effects were observed after 24 h ( l 3 ). 11,srnlogic an,llys1s of this model nf 111test111al mflammat1on ~howed the formation of uken, and profound ncutrophil 111filcrat1on. Arach1donic aud metabolism m coloniL mucosa from ,Kctic acid treated rats was Lomrared with that from normal rats. The normal rat mucns,t meta- There itrL' tw11 po1111s to hl' tak.L.·n frnm the stud1l'S of ,tra1.. h1don,lll' mera-hul1,m 111 I RD and .tll'tlc aL.1d u1ln1s.
Fust, th1..· ,1raL.h1,lo11ate nwtahnlncs 1;1rmed in JR!) mucusa arl h>rmcd primanl\ h\ compllnl'nts uf the acure rather than the dmmic port 11111 n( the 111tlammator~ re,pons1..• The most impllrt ,mt CL·llular co111p1111ent ,lppears to bl' d1t 11Cll[l"llJ)hil. Sl'(Ond, the pattern nf ar,1ch1dllnatl' metahol1sm sL·en m !RI) 11111c1b,I 1s rtllt spe1..ific tu lB[) and 1s pnihahly u1111mon ro .111 fm1rn, of intl'st111al 111tl.1mmat11ll1 with an acute c1 imponen t.
In the rh1rd ml1dl'I of col1us, m-tbm111at1<m 1s 111d11cL. ·d by adm1mstra-t1lln nl trin1tn1hcn:enesulphonic acid (TNRS). Rectal admmtstrauon ot a s1ngk Jo,l' of TNRS 111 rars mduces acutL.' uilms tiillnwcd hy Lhnm1L. colitts and then heal111g with stricture forma-t11111 Thrt'C wceb aftl'r adm111istrat1on 11t TNBS, ,lt ,1 t1m1..· \\ hen histologiL. assessment revenlcd chronic mflammatlon, macrnscop1l u1lu111c damage corrd,1ted with .m 111crease 111 synthesis of 6-keto PGFic, and L TB4 (15 ). Dady 111tracnlnnic treatment with a specific 5lipoxygcnasl' 111h1h1tor, l.651,392, during the first four day~ after iniuauon of thl' colitb with TNBS resulted in significant reJuct1<ms l)f° L TB 4 syn-tlws1s and u1l11n1c damage score ( 16 There arc sl'\'l'ral funLt 1onal and 1111, tologlL d1angl's seen 111 !BL) th,n may be pniducrs of the l'nh,mLed synthc,i; (lf lipuxygcnase pmJucts. One of the hallmarks of IIHl'sClnal 111tlammat inn m }.!Cnl'r,11 and lfi[) 111 part1cuJ.1r i, mucosa! edemn. The mucma 1s 1h1Ck· cned ,md. on L'nJoscopy, the \':lsllllar pattern 1s l1hsu1red. Among the ,11luhle mediators ot I ntlammat 1011 1 hat enhance , ascular rermeabd1t\ ,in: lu,-tam111e, C5a, hradyk111111 .md LTR.i ltb now dear that t hnc ts d1ffcrent1al ,u,, cept1bd1ty t1> enhancl' vascular r-:r· mcabil1ty m J1ffcrent organs. lnJL'Lllon ofL TB4 (3 µg/kg) into the left ventnde of rhe rat mJ11t.:ed enh.mceJ \'.lscular pern11..·ahd1ry 111 the ,km, the a1irra, 1he srom;Kh, t hl' small huwd an,I the cecum (I~). Thl· comh111,1t1on 11f L TBi and l'UE2 \\',ls n1<1rc rnrent than I TB;
al1me. In contr.tst, m·1ther PGl:.2 nor L TB4 had any l'ffocr on vascul.1r rcr· meahd1ry in the hra1n, he.1rt and r1..•,tcs Thw,, L TB4 may contnhute to en, hanl.l•d vasc11l,1r permeahd1ty in !RD.
Diarrhea .., a rmm111l'nt clinical tt.' :i· C,\r-;J G-\~TRtll!s:HRlll. V,11 7 Nll 2 F!:RRU,\RY l>lllJ ture of LBD anJ probably includes clements of both impaired absorption and enhanced secretion. The effects of lipoxygenase products on sail ,ind water flux in intestinal epithelium have not been fully explored. However, the first intermediate in the lipoxygenase pathway, 5-HPETE, ha~ been shown t,1 enhance chloride ~ecretion in the rabbit colon in vitro ( 19) .
Although they arc considered to he chronic inflammatory diseases the histologic picture of both Crohn's disease and ulcerative colitis include~ inteme neutrophil infiltration. In vivo studies with radiolabclled peripheral blood neutrophils demonstrate the movement of large numbers of neutrophils out of the circulation into the inflamed mucosa and the intestinal lumen (20) .
This process suggests the presence of a potent chemotactic agent in the intestinal mucosa which r,romotcs the passage of infiltrating neutrophils between endothelial cells, through the basement membrane and into the intestinal tissue.
Among the soluble mediators of inflammation that arc important neutrophil chemotactic agents arc: CSa, which is part of the complement cascade; bacterial-derived peptides including formylmethionlleucylphcnylalanine; and the arachidonate metabolites LTB4 (21) and 5-HETE. To determine which, if any, of these compounds was the mediator of neutrophil infiltration of the mucosa in IBD a study was performed using a Boyden chamber with 51Cr-labcllcd neutrophils in the upper chamber and either a chemoattractanr or buffer in the lower chamber (22) . Two filters, one on top of the other, separated the two chambers. After a 3 h incubation perio<l, the amount of rndioact1vity present in each filter was determined and the results expressed as the percent of total radioactivity present in the lower of the two filters. When buffer alone was present in the lower chamber almost none of the neutrophils penetrated the upper filter and entered the lower filter. When a chemotactic agent was present in the lower chamber a significant portion of the cells penetrated the upper fi l tcr and entered the lower. A dose-response curve w,1' obtained when various amounts of synthetic L TB4 were placed in the lower chamber. Next, homogenates of human colornc mucosa were added to the lower chamber at concentraunns of 2 mg/ml, 20 mg/ml and 100 mg/ml.
The chemotactic response to ulceranvc colitis mucosa was more than 20 times that to normal mucosa and the response to Crohn's colitis mucosa was more than 10 times that to normal mucosa.
To characterize the nature of the chemotactic agent in ulcerative colitis mucosa the chemotactic activity in homogenates of ulcerative colitis mucusa was compared to th,it in the lipid extracts of the homogenates.
Results showed chemotactic activity in the lipid extract to he between 78% and 90% of the chcmotactic activity in the total homogenate, suggesting that much of the chemotactic activity was present as a lipid. Fractions obtained by HPLC separntton of the lipid extracts from ulcerative colitis mucosa were utilized in the chemotaxis assay. Only the fraction that co-eluted with L TB4 contained a significant amount of chemurnctic activity, indicating that L TB4 was the predominant chemotactic agent in ulcerative colitis mucosa! extracts.
DRUG THERAPY OF IBO AND THE UPOXYGENASE PATHWAY
The two most widely used medical therapies for IBO arc corticosteroids and sulphasalazinc. Each Llf them block the synthesis of lipoxygcnase products in vitro, but each also has other r,harmacologic properties unrelated to arnchidonatc metabolism which may contribute to their therapeutic efficacy. Corticosteroids induce the synthesis of lipomodulin which blocks phospholipase AZ and thus limits the availability of arachidonatc, the substrate for the cyclooxygenasc and lipoxygenase pathways (1).
Sulphasalazine is metabolized to 5-ASA and sulphapyridine. While it is thought that sulphapyridinc is responsible for the unde:,irable side effect:, of sulphasalazinc and that 5-ASA is the therapeutic agent, there is substantial CAN] GASTROENTERl ll Vl)L 7 No 2 FEBRUARY 199 3
Leukotrine 84 in IBD evidence that tht: parent compound, ,ulphasalazine, possesses pharmacologic properties dbtinct from those of 5-ASA. Both sulphasalazme and 5-ASA inhibit cyclonxygenase and 5ltpoxygenase. In addimm, sulphasalazinc mhibits thromboxane ~ynthcrnse. One of the difficulties in determining therapeutically rcle\'ant pharmacologic effects is determ 111mg the appropri:He concentrations of the:,c compounds for study. In treated patients the concentration:, of these cnmpLlunds in stool are enormous, ie, l mm for sulr,hasalazinc and 1 OmM for 5-ASA (2 3 ). However, they are poorly ahsnrbed and the serum concentrations me quite low. Thus, high concentral inns nf thc~e agents arc observed on the lumenal side of the inflamed mucosa while, ar the same time, concentrations in the capillaries are minimal. The concentration of drugs to which relevam cells in the mucosa arc exposed is unclear.
When rested in in vitro assay systems at concentrations found in the colonic lumen these compound:, exert many pharmacologic effects, including inhihirion of arachidonic metabolism; however, when tested at concentrations found in the serum, their pharmacol,lgic effecb arc relatively minimal. For example, sulphasalazine inhibits a numhcr of steps in both the cyclooxygenllsc pathway aml the lipoxygenasc pathway at a concentration of approximately l mM, which is the cnncenmuion found in the colonic lumen hut ntit m the bloodstream. However, hoth corticosteroids and sulphasalazinc have other pharmacologic properties unrelated to arachidonate metabolism which may contribute to their therapeutic efficacy in IBD. Corticosteroids affect lymphocyte proliferation whereas sulphasalazine blocb lymphocyte cytoroxicity (24 ) .
Either of these effects could contribute to their therapeutic efficacy in IBD.
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